- More than 40 percent of coronavirus deaths in the U.S. linked to long-term care facilities; urgent need for therapeutic strategies to prevent COVID-19 in this vulnerable population   - First-of-its-kind study will enroll up to 2,400 residents and staff at long-term care facilities; will utilize

- Jardiance (empagliflozin) significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction   - Treatment of heart failure is an

New Alzheimer's disease blood test could enable early diagnosis and advance understanding of how disease impacts those living with it INDIANAPOLIS , July 28, 2020 /PRNewswire/ -- A new study on Lilly 's blood test for Alzheimer's disease (AD), P-tau217 (phosphorylated tau at threonine-217), was

Highlights include data that advance the understanding of Alzheimer's disease across the spectrum including early and accurate detection, diagnosis and treatment INDIANAPOLIS , July 21, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced that new results from 17 research studies

- Mirikizumab met the primary and all key secondary endpoints versus placebo at Week 16 and all key secondary endpoints versus Cosentyx® (secukinumab) at Week 16 and Week 52, including superiority in skin clearance at Week 52   - Lilly will submit data from OASIS-1 and 2 to regulatory authorities

Singer/songwriter Crystal Bowersox kicks off the educational initiative by encouraging people to educate their support network and develop a plan for low blood sugar and very low blood sugar emergencies INDIANAPOLIS , June 24, 2020 /PRNewswire/ -- About 34 million Americans live with diabetes, and

RIDGEFIELD, Conn. and INDIANAPOLIS, June 19, 2020 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced full results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials related to exercise ability and symptom improvement with Jardiance ® (empagliflozin) in

INDIANAPOLIS , June 17, 2020 /PRNewswire/ -- Emgality ® (galcanezumab-gnlm) reduces total pain burden in a recent analysis of patients with episodic and chronic migraine. Total pain burden is a patient-centric measure that combines the monthly frequency, duration, and pain severity of migraine.

- Data showed approximately 1 in 3 people diagnosed with migraine take a recommended acute prescription medication for a migraine attack, while less than 1 in 5 who suffer frequent migraine attacks take a recommended preventive prescription medication   - OVERCOME (Observational Survey of the

monarchE demonstrates positive results in Phase 3 study of 5,637 people whose early breast cancer is at a high risk of recurrence   Verzenio given with standard endocrine therapy showed improvement compared to standard endocrine therapy alone   Verzenio is the only CDK4 & 6 inhibitor to demonstrate